Emmanouela Repapi

Emmanouela Repapi

Auto-generated profile, based on publicly available information

Emmanouela Repapi

Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, Oxfordshire, OX3 9DS, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2017 in Nature Immunology
Verified
Journal Article
Open access
PDF file
DKDimitris Karamitros
Dimitris Karamitros
BSBilyana Stoilova
Bilyana Stoilova
ZAZahra Aboukhalil
Zahra Aboukhalil
FHFiona Hamey
Fiona Hamey
ARAndreas Reinisch
Andreas Reinisch
PVParesh Vyas
Paresh Vyas
The hierarchy of human hemopoietic progenitor cells that produce lymphoid and granulocytic–monocytic (myeloid) lineages is unclear. Multiple progenitor populations produce lymphoid and myeloid cells, but they remain incompletely characterized. Here we demonstrated that lympho-myeloid progenitor populations in cord blood — lymphoid-primed multi-potential progenitors (LMPPs), granulocyte-macrophage progenitors (GMPs) and multi-lymphoid progenitors (MLPs) — were functionally and transcriptionally distinct and heterogeneous at the clonal level, with progenitors of many different functional potentials present. Although most progenitors had the potential to develop into only one mature cell type (‘uni-lineage potential’), bi- and rarer multi-lineage progenitors were present among LMPPs, GMPs and MLPs. Those findings, coupled with single-cell expression analyses, suggest that a continuum of progenitors execute lymphoid and myeloid differentiation, rather than only uni-lineage progenitors’ being present downstream of stem cells.

3 August 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DCDaniele Corridoni
Daniele Corridoni
AAAgne Antanaviciute
Agne Antanaviciute
TGTarun Gupta
Tarun Gupta
DFDavid Fawkner-Corbett
David Fawkner-Corbett
AAAnna Aulicino
Anna Aulicino
ASAlison Simmons
Alison Simmons

26 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
LGLaura C Godfrey
Laura C Godfrey
NCNicholas T. Crump
Nicholas T. Crump
RTRoss Thorne
Ross Thorne
ILI-Jun Lau
I-Jun Lau
EREmmanouela Repapi
Emmanouela Repapi
TMTom Milne
Tom Milne
Enhancer elements are a key regulatory feature of many important genes. Several general features including the presence of specific histone modifications are used to demarcate potentially active enhancers. Here we reveal that putative enhancers marked with H3 lysine 79 (H3K79) di or trimethylation (me2/3) (which we name H3K79me2/3 enhancer elements or KEEs) can be found in multiple cell types. Mixed lineage leukemia gene (MLL) rearrangements (MLL-r) such as MLL-AF4 are a major cause of incurable acute lymphoblastic leukemias (ALL). Using the DOT1L inhibitor EPZ-5676 in MLL-AF4 leukemia cells, we show that H3K79me2/3 is required for maintaining chromatin accessibility, histone acetylation and transcription factor binding specifically at KEEs but not non-KEE enhancers. We go on to show that H3K79me2/3 is essential for maintaining enhancer-promoter interactions at a subset of KEEs. Together, these data implicate H3K79me2/3 as having a functional role at a subset of active enhancers in MLL-AF4 leukemia cells.

11 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
NCNicholas T. Crump
Nicholas T. Crump
EBErica Ballabio
Erica Ballabio
LGLaura Godfrey
Laura Godfrey
RTRoss Thorne
Ross Thorne
EREmmanouela Repapi
Emmanouela Repapi
TMTom Milne
Tom Milne
Enhancers are DNA sequences that enable complex temporal and tissue-specific regulation of genes in higher eukaryotes. Although it is not entirely clear how enhancer-promoter interactions can increase gene expression, this proximity has been observed in multiple systems at multiple loci and is thought to be essential for the maintenance of gene expression. Bromodomain and Extra-Terminal domain (BET) and Mediator proteins have been shown capable of forming phase condensates and are thought to be essential for super-enhancer function. Here, we show that targeting of cells with inhibitors of BET proteins or pharmacological degradation of BET protein Bromodomain-containing protein 4 (BRD4) has a strong impact on transcription but very little impact on enhancer-promoter interactions. Dissolving phase condensates reduces BRD4 and Mediator binding at enhancers and can also strongly affect gene transcription, without disrupting enhancer-promoter interactions. These results suggest that activation of transcription and maintenance of enhancer-promoter interactions are separable events. Our findings further indicate that enhancer-promoter interactions are not dependent on high levels of BRD4 and Mediator, and are likely maintained by a complex set of factors including additional activator complexes and, at some sites, CTCF and cohesin.

24 April 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
BYBon Ham Yip
Bon Ham Yip
VSVioletta Steeples
Violetta Steeples
EREmmanouela Repapi
Emmanouela Repapi
RARichard N. Armstrong
Richard N. Armstrong
MLMiriam Llorian
Miriam Llorian
JBJacqueline Boultwood
Jacqueline Boultwood
Mutations of the splicing factor–encoding gene U2AF1 are frequent in the myelodysplastic syndromes (MDS), a myeloid malignancy, and other cancers. Patients with MDS suffer from peripheral blood cytopenias, including anemia, and an increasing percentage of bone marrow myeloblasts. We studied the impact of the common U2AF1S34F mutation on cellular function and mRNA splicing in the main cell lineages affected in MDS. We demonstrated that U2AF1S34F expression in human hematopoietic progenitors impairs erythroid differentiation and skews granulomonocytic differentiation toward granulocytes. RNA sequencing of erythroid and granulomonocytic colonies revealed that U2AF1S34F induced a higher number of cassette exon splicing events in granulomonocytic cells than in erythroid cells. U2AF1S34F altered mRNA splicing of many transcripts that were expressed in both cell types in a lineage-specific manner. In hematopoietic progenitors, the introduction of isoform changes identified in the U2AF1S34F target genes H2AFY, encoding an H2A histone variant, and STRAP, encoding serine/threonine kinase receptor–associated protein, recapitulated phenotypes associated with U2AF1S34F expression in erythroid and granulomonocytic cells, suggesting a causal link. Furthermore, we showed that isoform modulation of H2AFY and STRAP rescues the erythroid differentiation defect in U2AF1S34F MDS cells, suggesting that splicing modulators could be used therapeutically. These data have critical implications for understanding MDS phenotypic heterogeneity and support the development of therapies targeting splicing abnormalities.

8 December 2017 in Science Immunology
Verified
Journal Article
Closed access
PDF file
CHClare S. Hardman
Clare S. Hardman
YCYi-Ling Chen
Yi-Ling Chen
MSMaryam Salimi
Maryam Salimi
RJRachael Jarrett
Rachael Jarrett
DJDavid Johnson
David Johnson
GOGraham Ogg
Graham Ogg
Group 2 innate lymphoid cells (ILC2) are effectors of barrier immunity, with roles in infection, wound healing, and allergy. A proportion of ILC2 express MHCII (major histocompatibility complex II) and are capable of presenting peptide antigens to T cells and amplifying the subsequent adaptive immune response. Recent studies have highlighted the importance of CD1a-reactive T cells in allergy and infection, activated by the presentation of endogenous neolipid antigens and bacterial components. Using a human skin challenge model, we unexpectedly show that human skin–derived ILC2 can express CD1a and are capable of presenting endogenous antigens to T cells. CD1a expression is up-regulated by TSLP (thymic stromal lymphopoietin) at levels observed in the skin of patients with atopic dermatitis, and the response is dependent on PLA2G4A. Furthermore, this pathway is used to sense Staphylococcus aureus by promoting Toll-like receptor–dependent CD1a-reactive T cell responses to endogenous ligands. These findings define a previously unrecognized role for ILC2 in lipid surveillance and identify shared pathways of CD1a- and PLA2G4A-dependent ILC2 inflammation amenable to therapeutic intervention.